Trial Profile
Molecular Correlates of Response to C225 (Erbitux or Cetuximab) in Combination With Cisplatin and Definitive Radiation in Unresectable Stage IV Squamous Cell Carcinoma of the Head and Neck (E3303): A Phase II Trial of Eastern Cooperative Oncology Group.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin
- Indications Head and neck cancer
- Focus Biomarker; Therapeutic Use
- 16 May 2017 Status changed from not yet recruiting to completed.
- 15 Sep 2010 New trial record